Escherichia coli: Development of Carbapenem Resistance During Therapy | Zendy

Tao Hong | Zendy; Ellen Smith Moland | Zendy; Baha Abdalhamid | Zendy; Nancy D. Hanson | Zendy; J. Wang | Zendy; Caroline E. Sloan | Zendy; Dušan Fabián | Zendy; Achmad Farajallah | Zendy; Jerome F. Levine | Zendy; Kenneth S. Thomson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Escherichia coli: Development of Carbapenem Resistance During Therapy

Author(s) -

Tao Hong,

Ellen Smith Moland,

Baha Abdalhamid,

Nancy D. Hanson,

J. Wang,

Caroline E. Sloan,

Dušan Fabián,

Achmad Farajallah,

Jerome F. Levine,

Kenneth S. Thomson

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/429822

Subject(s) - meropenem , imipenem , carbapenem , microbiology and biotechnology , escherichia coli , medicine , beta lactamase , enterobacteriaceae , antibiotics , antibiotic resistance , biology , gene , genetics

A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research